SIGA Technologies, Inc. (SIGA)
USD 6.4
(2.48%)
USD 6.4
(2.48%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 139.91 Million USD | 26.31% |
| 2022 | 110.77 Million USD | -17.13% |
| 2021 | 133.67 Million USD | 6.97% |
| 2020 | 124.95 Million USD | 367.28% |
| 2019 | 26.74 Million USD | -94.39% |
| 2018 | 477.05 Million USD | 3788.3% |
| 2017 | 12.26 Million USD | -18.14% |
| 2016 | 14.98 Million USD | 83.32% |
| 2015 | 8.17 Million USD | 160.39% |
| 2014 | 3.13 Million USD | -43.11% |
| 2013 | 5.51 Million USD | -38.48% |
| 2012 | 8.97 Million USD | -29.51% |
| 2011 | 12.72 Million USD | -33.77% |
| 2010 | 19.21 Million USD | 39.13% |
| 2009 | 13.81 Million USD | 71.24% |
| 2008 | 8.06 Million USD | 20.41% |
| 2007 | 6.69 Million USD | -7.7% |
| 2006 | 7.25 Million USD | -14.38% |
| 2005 | 8.47 Million USD | 360.9% |
| 2004 | 1.83 Million USD | 151.34% |
| 2003 | 731.74 Thousand USD | 112.44% |
| 2002 | 344.45 Thousand USD | -70.29% |
| 2001 | 1.15 Million USD | 140.0% |
| 2000 | 483.12 Thousand USD | -3.38% |
| 1999 | 500 Thousand USD | 0.0% |
| 1998 | 500 Thousand USD | -28.57% |
| 1997 | 700 Thousand USD | 600.0% |
| 1996 | 100 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 25.42 Million USD | -78.17% |
| 2024 Q2 | 21.81 Million USD | -14.23% |
| 2023 Q2 | 5.87 Million USD | -29.37% |
| 2023 Q3 | 9.23 Million USD | 57.11% |
| 2023 Q4 | 116.48 Million USD | 1161.27% |
| 2023 Q1 | 8.32 Million USD | -26.72% |
| 2023 FY | 139.91 Million USD | 26.31% |
| 2022 Q4 | 11.35 Million USD | -84.27% |
| 2022 FY | 110.77 Million USD | -17.13% |
| 2022 Q1 | 10.53 Million USD | -90.86% |
| 2022 Q2 | 16.66 Million USD | 58.14% |
| 2022 Q3 | 72.21 Million USD | 333.26% |
| 2021 Q3 | 4.84 Million USD | -44.0% |
| 2021 Q1 | 4.81 Million USD | -87.24% |
| 2021 Q2 | 8.65 Million USD | 79.76% |
| 2021 Q4 | 115.35 Million USD | 2280.38% |
| 2021 FY | 133.67 Million USD | 6.97% |
| 2020 Q1 | 2.61 Million USD | -38.56% |
| 2020 FY | 124.95 Million USD | 367.28% |
| 2020 Q3 | 44.26 Million USD | 9.7% |
| 2020 Q2 | 40.34 Million USD | 1440.17% |
| 2020 Q4 | 37.72 Million USD | -14.76% |
| 2019 Q4 | 4.26 Million USD | -47.43% |
| 2019 Q2 | 3.9 Million USD | -62.64% |
| 2019 Q1 | 10.45 Million USD | 566.48% |
| 2019 FY | 26.74 Million USD | -94.39% |
| 2019 Q3 | 8.11 Million USD | 107.58% |
| 2018 Q2 | 2.66 Million USD | 52.25% |
| 2018 FY | 477.05 Million USD | 3788.3% |
| 2018 Q1 | 1.74 Million USD | 23.76% |
| 2018 Q3 | 471.07 Million USD | 17601.51% |
| 2018 Q4 | 1.56 Million USD | -99.67% |
| 2017 FY | 12.26 Million USD | -18.14% |
| 2017 Q4 | 1.41 Million USD | 1.59% |
| 2017 Q3 | 1.39 Million USD | -67.4% |
| 2017 Q2 | 4.26 Million USD | -18.02% |
| 2017 Q1 | 5.2 Million USD | -27.33% |
| 2016 Q1 | 1.26 Million USD | -69.69% |
| 2016 FY | 14.98 Million USD | 83.32% |
| 2016 Q3 | 4.65 Million USD | 145.01% |
| 2016 Q2 | 1.9 Million USD | 49.74% |
| 2016 Q4 | 7.15 Million USD | 53.66% |
| 2015 FY | 8.17 Million USD | 160.39% |
| 2015 Q3 | 1.32 Million USD | -9.54% |
| 2015 Q1 | 1.19 Million USD | 41.85% |
| 2015 Q2 | 1.46 Million USD | 23.1% |
| 2015 Q4 | 4.18 Million USD | 215.57% |
| 2014 Q2 | 650.61 Thousand USD | 18.42% |
| 2014 Q1 | 549.41 Thousand USD | -41.18% |
| 2014 Q3 | 1.09 Million USD | 68.98% |
| 2014 Q4 | 840.37 Thousand USD | -23.56% |
| 2014 FY | 3.13 Million USD | -43.11% |
| 2013 Q1 | 1.32 Million USD | -47.16% |
| 2013 FY | 5.51 Million USD | -38.48% |
| 2013 Q2 | 964.66 Thousand USD | -27.38% |
| 2013 Q3 | 2.29 Million USD | 137.61% |
| 2013 Q4 | 934.12 Thousand USD | -59.25% |
| 2012 Q3 | 2.28 Million USD | -15.23% |
| 2012 Q1 | 1.46 Million USD | -70.45% |
| 2012 FY | 8.97 Million USD | -29.51% |
| 2012 Q4 | 2.51 Million USD | 9.79% |
| 2012 Q2 | 2.7 Million USD | 84.29% |
| 2011 Q4 | 4.96 Million USD | 38.63% |
| 2011 FY | 12.72 Million USD | -33.77% |
| 2011 Q3 | 3.57 Million USD | 43.63% |
| 2011 Q2 | 2.49 Million USD | 46.82% |
| 2011 Q1 | 1.69 Million USD | -44.59% |
| 2010 Q2 | 4.44 Million USD | -12.38% |
| 2010 Q1 | 5.07 Million USD | 28.32% |
| 2010 FY | 19.21 Million USD | 39.13% |
| 2010 Q4 | 3.06 Million USD | -53.83% |
| 2010 Q3 | 6.63 Million USD | 49.14% |
| 2009 Q2 | 4 Million USD | 108.17% |
| 2009 FY | 13.81 Million USD | 71.24% |
| 2009 Q4 | 3.95 Million USD | 0.85% |
| 2009 Q3 | 3.92 Million USD | -2.17% |
| 2009 Q1 | 1.92 Million USD | -22.61% |
| 2008 FY | 8.06 Million USD | 20.41% |
| 2008 Q4 | 2.48 Million USD | 33.61% |
| 2008 Q3 | 1.86 Million USD | 7.54% |
| 2008 Q2 | 1.73 Million USD | -12.64% |
| 2008 Q1 | 1.98 Million USD | 12.49% |
| 2007 Q3 | 1.6 Million USD | 10.24% |
| 2007 Q2 | 1.45 Million USD | -21.83% |
| 2007 Q1 | 1.86 Million USD | -21.16% |
| 2007 FY | 6.69 Million USD | -7.7% |
| 2007 Q4 | 1.76 Million USD | 9.53% |
| 2006 Q4 | 2.36 Million USD | 16.35% |
| 2006 Q2 | 1.45 Million USD | 4.62% |
| 2006 Q1 | 1.39 Million USD | -37.86% |
| 2006 FY | 7.25 Million USD | -14.38% |
| 2006 Q3 | 2.03 Million USD | 39.54% |
| 2005 Q2 | 1.86 Million USD | 27.8% |
| 2005 Q3 | 2.91 Million USD | 56.12% |
| 2005 Q4 | 2.24 Million USD | -22.88% |
| 2005 FY | 8.47 Million USD | 360.9% |
| 2005 Q1 | 1.45 Million USD | 72.26% |
| 2004 Q3 | 532.72 Thousand USD | 78.44% |
| 2004 Q4 | 846.7 Thousand USD | 58.94% |
| 2004 FY | 1.83 Million USD | 151.34% |
| 2004 Q1 | 161.21 Thousand USD | 51.06% |
| 2004 Q2 | 298.53 Thousand USD | 85.18% |
| 2003 Q3 | 176.34 Thousand USD | -27.59% |
| 2003 Q1 | 205.14 Thousand USD | 77.78% |
| 2003 Q4 | 106.72 Thousand USD | -39.48% |
| 2003 FY | 731.74 Thousand USD | 112.44% |
| 2003 Q2 | 243.53 Thousand USD | 18.71% |
| 2002 Q1 | - USD | -100.0% |
| 2002 FY | 344.45 Thousand USD | -70.29% |
| 2002 Q4 | 115.39 Thousand USD | 28.59% |
| 2002 Q3 | 89.73 Thousand USD | -35.59% |
| 2002 Q2 | 139.31 Thousand USD | 0.0% |
| 2001 Q1 | 304.5 Thousand USD | 156.73% |
| 2001 FY | 1.15 Million USD | 140.0% |
| 2001 Q4 | 15 Thousand USD | -90.48% |
| 2001 Q3 | 157.5 Thousand USD | -76.92% |
| 2001 Q2 | 682.5 Thousand USD | 124.14% |
| 2000 Q2 | 90.37 Thousand USD | 11.85% |
| 2000 Q1 | 80.8 Thousand USD | -19.2% |
| 2000 FY | 483.12 Thousand USD | -3.38% |
| 2000 Q3 | 193.34 Thousand USD | 113.94% |
| 2000 Q4 | 118.6 Thousand USD | -38.65% |
| 1999 Q4 | 100 Thousand USD | 0.0% |
| 1999 Q1 | 100 Thousand USD | -50.0% |
| 1999 FY | 500 Thousand USD | 0.0% |
| 1999 Q3 | 100 Thousand USD | 0.0% |
| 1999 Q2 | 100 Thousand USD | 0.0% |
| 1998 Q4 | 200 Thousand USD | 100.0% |
| 1998 Q1 | 100 Thousand USD | -66.67% |
| 1998 Q2 | 100 Thousand USD | 0.0% |
| 1998 Q3 | 100 Thousand USD | 0.0% |
| 1998 FY | 500 Thousand USD | -28.57% |
| 1997 FY | 700 Thousand USD | 600.0% |
| 1997 Q1 | 100 Thousand USD | 0.0% |
| 1997 Q2 | 100 Thousand USD | 0.0% |
| 1997 Q3 | 400 Thousand USD | 300.0% |
| 1997 Q4 | 300 Thousand USD | -25.0% |
| 1996 FY | 100 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 69.869% |
| PainReform Ltd. | - USD | -Infinity% |
| Alvotech | 91.43 Million USD | -53.025% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 75.313% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 71.259% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -176.609% |
| Journey Medical Corporation | 79.18 Million USD | -76.706% |
| Dynavax Technologies Corporation | 232.28 Million USD | 39.765% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -20.272% |
| Bright Green Corporation | 401.49 Thousand USD | -34749.404% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 79.271% |
| Embecta Corp. | 1.12 Billion USD | 87.516% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -480.743% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -480.743% |
| SCYNEXIS, Inc. | 140.14 Million USD | 0.16% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -2303.09% |
| Silver Spike Investment Corp. | 11.72 Million USD | -1093.616% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -7155.247% |
| Alpha Teknova, Inc. | 36.68 Million USD | -281.412% |
| Safety Shot Inc | 202.67 Thousand USD | -68936.966% |
| Procaps Group, S.A. | 409.92 Million USD | 65.867% |
| Cosmos Health Inc. | 53.37 Million USD | -162.131% |
| Theratechnologies Inc. | 81.76 Million USD | -71.123% |
| Harrow Health, Inc. | 130.19 Million USD | -7.469% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -998.683% |
| Biofrontera Inc. | 34.07 Million USD | -310.664% |
| DURECT Corporation | 8.54 Million USD | -1536.842% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 76.969% |
| Cronos Group Inc. | 88.84 Million USD | -57.492% |
| OptiNose, Inc. | 70.98 Million USD | -97.103% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 68.397% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -2048.219% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 67.697% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -1042.317% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -253.751% |
| Radius Health, Inc. | 2.88 Billion USD | 95.146% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -333.063% |
| ProPhase Labs, Inc. | 44.38 Million USD | -215.242% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 86.251% |
| Procaps Group S.A. | 409.92 Million USD | 65.867% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -10646.33% |
| Viatris Inc. | 15.42 Billion USD | 99.093% |
| Rockwell Medical, Inc. | 83.61 Million USD | -67.341% |
| Aytu BioPharma, Inc. | 81 Million USD | -72.733% |
| Tilray Brands, Inc. | 788.94 Million USD | 82.265% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -9.088% |
| Shineco, Inc. | 9.8 Million USD | -1327.456% |
| PetIQ, Inc. | 1.1 Billion USD | 87.303% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -1165876.833% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 92.586% |
| Alimera Sciences, Inc. | 80.75 Million USD | -73.264% |
| Assertio Holdings, Inc. | 152.06 Million USD | 7.991% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -703.337% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -12898.567% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -400.366% |
| Hempacco Co., Inc. | 4.04 Million USD | -3358.472% |
| Talphera, Inc. | 651 Thousand USD | -21392.661% |
| Alvotech | 91.43 Million USD | -53.025% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 55.808% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 89.207% |
| Currenc Group, Inc. | 53.25 Million USD | -162.729% |
| Kamada Ltd. | 144.75 Million USD | 3.345% |
| Indivior PLC | 1.09 Billion USD | 87.199% |
| Evoke Pharma, Inc. | 5.18 Million USD | -2600.776% |
| Flora Growth Corp. | 76.07 Million USD | -83.93% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -12898.567% |
| Evolus, Inc. | 202.08 Million USD | 30.763% |
| HUTCHMED (China) Limited | 837.99 Million USD | 83.303% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 78.287% |
| Akanda Corp. | 2.16 Million USD | -6377.493% |